March 29, 2021 09:52 AM EDTUpdated March 30, 05:45 AM
R&D
Coronavirus

Eli Lil­ly, Glax­o­SmithK­line-Vir re­lease pos­i­tive but dif­fi­cult-to-in­ter­pret com­bo an­ti­body da­ta

Jason Mast

Editor

As vari­ants threat­ened Eli Lil­ly’s so­lo Covid-19 an­ti­body bam­lanivimab, the com­pa­ny teamed with ri­vals on a po­ten­tial com­bo ap­proach. Now they’ve de­clared in­ter­im suc­cess, though …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times